期刊
ONCOTARGET
卷 6, 期 5, 页码 2709-2724出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2779
关键词
PDGFR; c-MYC; JAG2; miR-1280; medulloblastoma
资金
- National Center for Research Resources (NCRR) from the National Institutes of Health (NIH) [P20 RR020151]
- National Institute of General Medical Sciences (NIGMS) from the National Institutes of Health (NIH) [P20 GM103505]
- Mildred-Scheel foundation / German Cancer Aid
- V Foundation for Cancer Research
- National Institute of Dental & Craniofacial Research of NIH [R01DE023641]
- CIHR Clinician Scientist Phase II award
- Garron Family Chair in Childhood Cancer Research at The Hospital for Sick Children
- University of Toronto
- Canadian Institutes of Health Research
- NIH [R01CA159859, R01CA148699]
- Pediatric Brain Tumor Foundation
Over-expression of PDGF receptors (PDGFRs) has been previously implicated in high-risk medulloblastoma (MB) pathogenesis. However, the exact biological functions of PDGFRa and PDGFR beta signaling in MB biology remain poorly understood. Here, we report the subgroup specific expression of PDGFRa and PDGFR beta and their associated biological pathways in MB tumors. c-MYC, a downstream target of PDGFR beta but not PDGFRa, is involved in PDGFR beta signaling associated with cell proliferation, cell death, and invasion. Concurrent inhibition of PDGFR beta and c-MYC blocks MB cell proliferation and migration synergistically. Integrated analysis of miRNA and miRNA targets regulated by both PDGFR beta and c-MYC reveals that increased expression of JAG2, a target of miR-1280, is associated with high metastatic dissemination at diagnosis and a poor outcome in MB patients. Our study may resolve the controversy on the role of PDGFRs in MB and unveils JAG2 as a key downstream effector of a PDGFR beta-driven signaling cascade and a potential therapeutic target.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据